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abstract

PURPOSE Disparities in radiation oncology (RO) can be attributed to geographic location, socioeconomic status,
race, sex, and other societal factors. One potential solution is to implement a fully mobile (FM) RO system to
bring radiotherapy to rural areas and reduce barriers to access. We use Monte Carlo simulation to quantify
techno-economic feasibility with uncertainty, using two rural Missouri scenarios.
METHODS Recently, a semimobile RO system has been developed by building an o-ring linear accelerator (linac)
into a mobile coach that is used for temporary care, months at a time. Transitioning to a more FM-RO system,
which changes location within a given day, presents technical challenges including logistics and quality assurance. This simulation includes cancer census in both northern and southeastern Missouri, multiple
treatment locations within a given day, and associated expenditures and revenues. A subset of patients with
lung, breast, and rectal diseases, treated with ﬁve fractions, was simulated in the FM-RO system.
RESULTS The FM-RO can perform all necessary quality assurance tests as suggested in national medical physics
guidelines within 1.5 hours, thus demonstrating technological feasibility. In northern and southeastern Missouri,
ﬁve-fraction simulations’ net incomes were, in US dollars (USD), $1.55 6 0.17 million (approximately 74 patients/
year) and $3.65 USD 6 0.25 million (approximately 98 patients/year), respectively. The number of patients seen
had the highest correlation with net income as well as the ability to break-even within the simulation. The model does
not account for disruptions in care or other commonly used treatment paradigms, which may lead to differences in
estimated economic return. Overall, the mobile system achieved a net beneﬁt, even for the most negative simulation
scenarios.
CONCLUSION Our simulations suggest technologic success and economic viability for a FM-RO system within rural
Missouri and present an interesting solution to address other geographic disparities in access to radiotherapy.
JCO Global Oncol 8:e2100284. © 2022 by American Society of Clinical Oncology
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Access to radiotherapy is subject to disparities
associated with geographic location, socioeconomic status, age, race, sex, and a variety of other
social factors. 1-3 Among these, geographic location,
particularly rural locations, can reduce access to
care, in part because of travel burdens for multiple,
daily visits to a distant facility for extended treatment
processes typical of radiotherapy.4,5 In 2014,
Johnson et al5 showed that rural residents were
1.6 times more likely to have an incompletely staged
disease and were less likely to receive indicated
radiotherapy compared with urban patients. Potential strategies to limit geographic disparity include building cancer centers in areas of need but
can be cost-prohibitive to health care networks. The
development of compact linear accelerators
(linacs) mounted within a semitrailer may represent

a cheaper and more comprehensive treatment alternative to lessen geographic disparities.6
Alliance Oncology (Irvine, CA) has taken initial steps
toward this goal by implementing mobile radiation
oncology (RO) units within an interim setting. In their
system, compact, ring gantry linacs (Halcyon, Varian
Medical Systems, Palo Alto, CA) are mounted on
tractor trailers and then transported to clinics, where
they are parked in a semipermanent concrete
shielding structure for clinical use and provide radiation protection.6 This semipermanent model is
intended to provide smaller RO clinics, undergoing
planned technology outages (ie, for an upgrade of their
existing, permanent linacs), with the ability to maintain
treatments. The linac, equipment, and console are all
contained within the semitrailer. At locations of interest, additional lead shielding is placed within the
semitrailer, which takes roughly 24 working hours. The
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CONTEXT
Key Objective
To explore the feasibility of a mobile radiation oncology system in lower resource areas.
Knowledge Generated
This report demonstrates that mobile radiation oncology is both technologically and economically feasible. However, one must
consider the patient population and resource limitations before implementation since these factors can affect relative
success.
Relevance
These results can generate momentum for expanding radiation oncological use in low-resource areas across the world.

semitrailer is stationary throughout its duration at a single
location, which could range from several months to a year.
To date, this semimobile linac system has been successfully used for treatment in three locations across the
United States.
At present, there has been no comprehensive evaluation
of the feasibility of a fully mobile (FM) RO system that
could ﬂexibly relocate a compact linac on a weekly or
daily basis. Such an increase in the geographic range of a
mobile linac could, in theory, increase access to care and
reduce travel times for patients.7-9 The proposed system
evaluated here would be supported by a larger medical
institution and function as a regional satellite clinic. To
limit disparities between the mobile system and a brickand-mortar facility, the mobile system should be capable
of providing state-of-the-art treatment techniques, such
as intensity-modulated radiotherapy and stereotactic
body radiotherapy (SBRT).
Here, we demonstrate the techno-economic feasibility of a
FM RO system design using Monte Carlo simulation to
estimate uncertainty and to explore how these uncertainties
affect feasibility. For technical capability, logistic testing
and quality assurance are investigated. For economic
feasibility, we model a mobile linac system-based clinic and
workﬂow within two rural Missouri scenarios.
METHODS
Simulation Scope
We simulate two scenarios, one focused on northern
Missouri and the other on southern Missouri (Fig 1), which
currently lack regional RO facilities. Each region provides a
different cancer patient census, affecting the type and
number of patients seen. Within both regions, three distinct
locations were selected to create a triangular coverage
pattern, in which the mobile RO system could dock to
provide treatment and ensure similar travel distances to
each docking location. Locations were chosen so travel
from surrounding counties was , 1.5 hours. At the beginning of each week, two locations were randomly selected as locations of treatment for the week. Treatment
was modeled as occurring at one location in the morning,
and then the second in the afternoon. The third location

was not used during week 1. In the following week, the third
location was used for treatment in addition to one of the
previous two treatment locations. All subsequent weeks in
the simulation modeled this care pattern. The procedure for
system setup and stafﬁng at each location are included
in Data Supplement. Conﬁguration of the system setup is
illustrated in Figure 2.
Each run of the Monte Carlo simulation included a 5-year
life cycle of the mobile system. This assumes that mobile
linacs would have shorter life cycles compared with stationary linacs, which typically follow a 10-year depreciation
pattern. The simulation was written in Python Tools for
Visual Studio (Microsoft, Redmond, WA). Figure 3 illustrates the simulation workﬂow.
Model Inputs
Shielding requirements/costs are included within the
model, and a more in-depth discussion regarding shielding
is included in Data Supplement.
Next, we estimated annual patient loads (Fig 3C). Only
relevant deﬁnitive ﬁve-fraction treatment regimens were
considered for breast,10 lung,11 and rectal12 disease sites
because of the simplicity of scheduling within a given work
week. Only weeks with a full 5 working days were considered in our simulation, that is, we would plan to not treat
during weeks with holidays. The patient cancer census
was gathered from the Cancer Incidence Missouri Information for Community Assessment website from the
Missouri Department of Health and Senior Services.13 This
provided the cancer incidence rates and 95% CI per
100,000 population per treatment site in each county of
Missouri over the last 20 years. Population census data
were gathered from the US Census Bureau Data. The
number of patients per year was randomly drawn from a
Gaussian distribution with a mean-centered at the yearly
rate and the standard deviation derived from the 95% CI for
each disease site investigated provided in Table 1. The
likelihood of receiving radiotherapy for a given disease
stage was extracted from the recent literature (Table 2).14
All costs related to the mobile aspect of the system are
shown in Table 3. This includes costs of the linac truck
(L-truck), clinical truck (C-truck), construction, and
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FIG 1. Map of Missouri containing the two separate geographic locations. Shaded in blue is the area that the northern mobile linac would serve while
the area shaded in red is the area that the southern mobile linac would serve. Stars represent where the linac would be docked.

operations. Because of uncertainty surrounding the cost of
the L-truck, C-truck, and construction on the basis of
vendor and design, uniform distributions were used to
approximate costs. Cost-per-mile variables were estimated
from the operational costs of trucking in the literature.15
Data Supplement summarizes the expenditure data within
the system in Data Supplement. When traveling from one
location to the next, beta distributions were applied to the
time traveled/setup time and maintenance to introduce
longer outlier times and maintenance costs.
Reimbursement from both Centers for Medicare & Medicaid
Services recently proposed the RO alternative payment model
and fee-for-service private insurance were included to better
understand differences in payment models.16-18 At the end of

each year, the total cost of operation was subtracted from the
total earnings to estimate a net income.
Sensitivity analyses reporting the percent change in cost
between using minimum and maximum values for each
parameter were conducted to identify factors with high
potential inﬂuence. For patient populations, two standard
deviations from the mean were used as the extremes. All
other extremes were either extracted from the literature,15,19
deﬁned system constraints, or from vendor quotes
(Table 4). In addition, a variety of simulations were performed within northern and southern Missouri to determine
break-even scenarios for the system in each geographic
location. This included iterating the number of patients,
from zero patients to each disease site’s average and
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Console and medical truck (C-Truck)

Hallway

FIG 2. System conﬁguration. The linac
truck (L-Truck) contains the linac,
whereas the clinical truck (C-Truck)
contains both the treatment console and
clinic room. The black star represents
possible locations of radiation survey
measurements.

Distance to concrete
Distance to radiation measurement

Linac

Mobile coach (L-Truck)

Concrete bay

insurance types: 25% private insurance to 75% private
insurance, reporting the resulting system proﬁt.
RESULTS
Technological Implementation
Table 5 illustrates a combination of daily, monthly, multileaf
collimator, and imaging tests along with their tolerances
that are described in Task Group-142 (TG-142) as well as
the corollary tests performed during the Machine Performance Check (MPC).20-22 Additionally, a secondary quality
assurance (QA) device, such as the Sun Nuclear ArcCheck
(Sun Nuclear Corporation, Melbourne, FL) with a WinstonLutz attached end piece, is included denoting whether or
not the device could perform the TG-142 test.
In total, MPC and a secondary QA delivery system can be
performed in less than 30 minutes. When considering setup
time and QA beam delivery, the total time from arrival to
treatment ready would be 2.5 hours for the worst-case
scenario such as delays in docking or trouble with connections. When done twice, that equals 5 hours of nontreatment time with 1 hour of travel time during the work day.
Despite only leaving 4 hours for treatment, previous studies
reported that imaging and treatment times on the Halcyon
unit for both breast and gynecologic patients can be

performed in under 5 minutes, respectively.23,24 Considering
patient setup time, imaging, treatment, and patient exit, most
standard fractionation patients can complete treatment in
around 10 minutes and SBRT style dosing can be ﬁnished in
20 minutes. With 4 hours for treatment, upward of 12 patients
can be treated depending on the modality and site, which is
greater than the number of patients seen in a given day
during simulation.
Economic Feasibility
Figure 4 illustrates results for simulations run in both
northern and southern Missouri. In the northern region, the
average annual revenue was $1.55E6 in US dollars (USD)
6 $1.65E5 USD. The average number of patients seen was
74.6 6 0.0 patients. In the southern region, the average
annual revenue was higher at $3.65E6 USD 6 $2.46E5
USD. The average number of patients seen was also higher
in the southern region at 98.6 6 0.1. In both simulations,
there were no simulations where annual proﬁts were
negative. Additionally, there were no scenarios where patient treatment had to be postponed due to trafﬁc patterns
or delays in machine setup.
In the southern Missouri sensitivity analysis, the number of
lung patients had the highest impact on a change in overall
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Simulation code
A) Simulation run × 10,000

Calculate construction costs for three concrete treatment bays

B) 5-year simulation

All expenses/charge increase 1.03 per year and patient load

C) Within a given work week of 5 days

Regional cancer
census
information

Site
modality
Fx No.
treatment time
APM payment

Create patient

Generate
revenue

D) Within a day

Calculate setup
time
Calculate
distance-related
expenditures

Locations of
treatment

Determine if all
patients can be
treated in time

Calculate travel
time

FIG 3. The simulation workﬂow for a mobile radiation oncology system illustrating the sublevel iterations needed to run the Monte Carlo system.
Fx, number of fractions; APM, alternative payment model.

cost to the system, followed by insurance type, number of
breast patients, and number of rectum patients. The
concrete position, C-truck, and ﬂuctuation in operational
costs had the lowest impact on change in overall costs to
the system. Detailed results are summarized in Table 4.
Results of break-even analyses for both northern and
southern Missouri are shown in Figure 5. Increasing the
number of patients treated results in increased proﬁt.
Additionally, increased private insurance populations also
increase the proﬁt. This ﬁgure also illustrates how the
number of patients or the ratio of insurance type differs for
TABLE 1. Breast, Lung, and Rectal Cancer Incidence Rates in Both Northern and
Southern Missouri
Breast
Lung
Rectum
Variable

Northern Southern Northern Southern Northern Southern

different locations, which affects potential economic
viability.
DISCUSSION
In this study, we estimated the techno-economic feasibility
of a fully mobile RO system. On the basis of a thorough
quality assurance overview and a timing analysis of setup
and treatment times, we have demonstrated that it is
possible to adequately verify safe treatment delivery while
also having enough time to treat patients. Economically, the
simulations performed demonstrate ﬁnancial viability of a
TABLE 2. Likelihood That an Individual Would Receive Radiotherapy
for the Various Disease Sites Investigated in This Study
Site
Staging
Staging, %
Receiving RT, %
Breast

1-2

77

49

Rate

79.02

84.83

73.04

131.63

11.25

20.89

Lung

1-2

25

31

Lower 95% CI

74.13

78.67

68.56

123.94

9.51

17.94

Rectum

2-4

65

100

Upper 95% CI

83.92

91.00

77.51

139.31

13.22

24.18

Abbreviation: RT, radiotherapy.
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TABLE 3. Costs Relating to the Mobile Unit
Item

Lower Bound

Upper Bound

Unit

Linac truck

3,000,000

5,000,000

$

Clinical truck

400,000

500,000

$

Truck maintenance

0.124

0.171

$/mi

Truck gas

0.336

0.645

$/mi

Truck insurance

0.059

0.084

$/mi

Permits and licenses

0.019

0.040

$/mi

Tires

0.035

0.044

$/mi

Concrete construction

850

2,994

$/yd3

NOTE. Each item has lower and upper bounds of the uniform
distribution.
Abbreviation: $,US dollars.

fully mobile RO system, generating positive proﬁts in every
year of simulation.
Most health care facilities will have both power and internet
connections; however, health care facilities may not be
present in areas of interest and should be heavily considered before implementation. Health care planners might
have to look at other non-health care–related locations
with both power and internet if needed to provide this
crucial service. Availability of stafﬁng and transportation
infrastructure must also be considered during planning.
There are resources available to help optimize the location
of a health care facility that can be applied in project
planning.25-29 Since the machine is built into the truck,
accepted, and commissioned all before the ﬁrst treatment,
during setup, only connections, level adjustments, and a

series of constancy checks are needed to demonstrate that
the machine meets baseline performance standards set at
the time of commissioning. Not incorporating the lead into
the L-truck requires the need for a C-truck for safety issues,
which introduces higher logistical and risk concerns but will
help increase the temporal mobility of the system and reach
a larger patient population
Over time, the linac may incur more wear from repeated
setup and travel damages. Because of this concern, the
linac would be tested more rigorously at a higher frequency
compared with linacs at standard brick and mortar facilities. Both the MPC and secondary QA check would provide
detailed constancy trends of the L-linac over time to potentially identify when preventative maintenance is needed.
The low patient volume and decreased treatment times
could in theory improve the ﬂexibility of when maintenance
occurs or when patients are scheduled if needed.
To base our simulations closer to reality, the simulations are
rooted in the cancer census data in both northern and
southern Missouri. It is inappropriate to assume that there
will be an acceptable patient load with the use of the system
without modeling its implementation. We also see how
patient make-ups including both disease and insurance
type affects break-even points. With that said, our model
was limited by only considering ﬁve fractions or less lung,
breast, and rectal cases at ﬁrst which is a small portion of
the RO patient population as a whole. Extending past ﬁve
fraction treatments or to palliative treatment courses introduces additional scheduling and human interaction/
compliance issues, which could be an area of future
research.

TABLE 4. Parameters Used Within the Sensitivity Analysis Along With Its Standard Value and Range
Parameter

Standard Value

Min, Step, Max

Patients with lung cancer

36

11.7, 2.6, 60.6

Insurance type

30%

10%, 2.105%, 50%

Change Cost, %
69.30
–39.8

Patients with breast cancer

45

14.5, 3.2, 74.8

34.2

Patients with rectal cancer

20

6.9, 1.4, 32.5

16.2

Linac truck

$4,000,000

$3,000,000, $105,263, $5,000,000

–6.3

Shielding cost

$1,922/yd3

$800/yd3, $115.8/yd3, $3,000/yd3

–2.7

Dose measurement X1

9.05 m

2.8 m, 0.658 m, 15.3 m

Dose measurement X2

9.05 m

2.8 m, 0.658 m, 15.3 m

Dose measurement Y1

10.95 m

6.6 m, 0.458 m, 15.3 m

Dose measurement Y2

14.05 m

12.8 m, 0.132 m, 15.3 m

Concrete position X1

8.75 m

2.5 m, 0.658 m, 15 m

Concrete position X2

8.75 m

2.5 m, 0.658 m, 15 m

Concrete position Y1

10.65 m

6.3 m, 0.458 m, 15 m

Concrete position Y2

13.75 m

12.5 m, 0.132 m, 15 m

Clinical truck

$450,000

$400,000, $5,263, $500,000

Operational costs

1

0.97, 0.003, 1.03

2.8

0.8

–0.5
0.6

NOTE. The results of the linear regression analysis are given within this table, along with the index of standardized sensitivity and the impact on
total cost.
Abbreviation: $, US dollars.
6 © 2022 by American Society of Clinical Oncology
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TABLE 5. Tests Deﬁned in TG-142 and Associated Tolerances Deﬁned in TG-142 and the MPC Tolerances
Tests to Be Performed
Test

TG-142 Tol.

MPC Tol.

External QA

3%

4%

Yes

Daily
X-ray output constancy
Laser localization

1 mm

2 mm

Yes

Collimator size indicator

1 mm

1 mm

Yes

Door interlock

Functional

NA

NA

Audio-visual monitors

Functional

NA

NA

Beam-on indicator

Functional

NA

NA

Monthly
X-ray output constancy

2%

4%

Yes

Backup monitor chamber

2%

10%

No

Typical dose rate output

NA

NA

NA

Photon beam proﬁle constancy

1%

2%

Yes

Gantry angle indicators

1.0°

0.5°

Yes

Collimator angle indicators

1.0°

0.5°

Yes

Collimator walkout

1 mm

0.5°

Yes

Treatment couch indicators

1 mm

0.5 mm (short) and 1.0 mm (long)

Yes

Localizing lasers

1 mm

2 mm

Yes

Weekly qualitative test

Visual

0.9 mm (prox) and 0.8 mm (dist)

Yes

Monthly MLC position v radiation

2 mm

0.55 mm (prox) and 0.6 mm (dist)

Yes

Imaging v treatment isocenter coincidence

1 mm

0.9 mm

Yes

Position/reposition

1 mm

0.5 mm (short) and 1.0 mm (long)

Yes

MLC

Imaging

NOTE. The external QA column denotes whether those tests can be performed on that device.
Abbreviations: MLC, multi-leaf collimator; NA, not available; QA, quality assurance; TG-142, Task Group-142.

In the sensitivity analysis, patient and insurance type are
the largest drivers for impact on total proﬁt considering
those variables control proﬁt. Patients with lung disease are
the greatest drivers due in part to the higher reimbursement
return on investment for SBRT and the sheer number of
patients needing treatment in southern Missouri. This is
also shown in the break-even analysis for both northern and
southern Missouri where patients with breast and lung
diseases had a much higher impact on proﬁt and could be
economically viable without any rectal patients. This would
not be the case in northern Missouri, demonstrating that
placing a mobile system in an area of interest will not automatically guarantee a viable system. One must perform this
type of analysis before the implementation of a FM RO
system in the geographic area of interest as part of the
planning phase. Ignoring patient ﬂow patterns and the
current standard of care in these regions is a limitation of this
work that is being addressed in future modeling studies.
There is still signiﬁcant uncertainty in the parameter
values, which is why we estimated distribution of outcomes
using Monte Carlo simulation. When considering that the

semimobile linac solution has only been physically moved
three times, the data are sparse in terms of experience to
inform the technical challenges that our proposed solution
would provide. However, our investigation did look at
mobile mammography and positron emission tomography/
computed tomography to understand the mobile impact
on maintenance and additional costs, which were introduced into our simulation. For other variables that were not
known for certain, such as the cost of the L-truck or
construction costs, a uniform distribution was implemented within the model, meaning that all scenarios were
equally likely to occur. This approach captures the greater
range of uncertainties within the system for investigation.
Despite this conservative approach, our simulations suggest this is an economically viable system.
Ultimately, there are three types of delays that may inﬂuence patient care and system proﬁtability, conditions that
affect (1) the patient and mobile system equally, (2) the
mobile system, and (3) the patient. These types of delays
are not fully modeled in the present simulation and may
lead to an overestimation of effectiveness. Conditions that

JCO Global Oncology
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FIG 4. Plots of simulations results for both northern and southern Missouri: (A) a histogram showing northern Missouri average annual proﬁt, (B) a histogram
of the average number of patients seen per year in northern Missouri, (C) a histogram showing southern Missouri average annual proﬁt, and (D) a histogram of
the average number of patients seen per year in southern Missouri. $, US dollars.

affect both the patient and mobile systems equally, such as
weather, are likely to lead to unavoidable delays in care. For
example, if the mobile system cannot travel to the patient
because of a snowstorm, the patient is likely also unable to
travel to a brick-and-mortar facility. We expect this to represent
a small number of cases and not inﬂuence a comparison
between mobile and brick-and-mortar facilities. Conditions that
affect the mobile system, such as trafﬁc or emergency
maintenance, are a key concern for this analysis. The present
analysis uses Beta distributions to include the uncertainty of
high impact, low likelihood events. If the L-linac is down for
maintenance or the mobile system faces other difﬁculties such
as a trafﬁc accident or C-truck maintenance, the mobile

system could stay at the two current locations for the
following week to prevent these patients from having to
travel to a separate location, further away. Conditions that
affect the patient, such as a missed appointment, would
have to be resolved by the patient. For example, if a patient
were to miss the treatment, the patient may have to travel
to a separate location the following week if the system does
not travel back to the patient’s location the following week.
In a recent study of 427 patients receiving ﬁve fractions or
less, only 3.7% of those patients missed two fractions or
more,1 which may translate to a small percentage of our
simulated patients missing treatments. When a patient
misses the treatment, some may wait for at least a week or

8 © 2022 by American Society of Clinical Oncology
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FIG 5. Break-even analyses for all six scenarios investigated: (A) breast versus lung, (B) breast versus rectum, (C) lung versus rectum, (D) lung versus
insurance, (E) breast versus insurance, and (F) rectum versus insurance. In the top row, the area point to the top right indicates increasing income. In the
bottom row, the arrow pointing to the top left indicates the direction of increasing income. Each line within the graph represents the line at which a positive
proﬁt is made based on varied parameter on the x- and y-axes. An insurance ratio of 0.25 means that the clinical makeup for the patient population would be
25% private insurers and 75% Medicare/Medicaid-based.

two for the mobile system to return to their location if they
are not willing to travel to a separate location. Patients may
also not ﬁnish their treatment because of the mobile system
moving to another location because they are lost to follow
up. This would have both a negative ﬁnancial and health
outcome to the system and patient, respectively. With this
in mind, our model is most likely overestimating the overall
success on average but our estimated uncertainties capture the extremes of the mobile system that still demonstrate an overall net beneﬁt.
There are also other patient-related clinical care decisions
that affect the success of the overall system. For example,
simulation and resimulation may prove to be challenging
with only a cone-beam computed tomography imager.
However, recent research on the use of diagnostic imaging
for planning and simulation-free techniques could be appropriately used to improve the efﬁciency of the system.30-32
For treatment monitoring, telehealth and remote symptom
monitoring applications could be used to aid in managing

the patients’ health during treatment.33,34 Although, the
effectiveness may be limited by patient access to internet
service or willingness to participate in telemedicine.
To date, this novel fully mobile approach to RO has not
been discussed in the literature. Fully mobile RO is now a
possibility within the ﬁeld and would have substantial impacts not only on rural health care but also within developing countries. The fully mobile system could adjust to
regional demands of cancer treatment and provide a more
cost-effective approach to the delivery of care. Our work is
important in that we are simulating the life-cycle of a fully
mobile RO system rooted in cancer census speciﬁc to the
area of interest, which is the driver of economic viability for
such a system. Our future work will be to model the health
care infrastructure in rural Missouri to understand how the
deployment of a fully mobile RO system would affect infrastructure, decision making, and health care in the
region.
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